Neurotrope is a front for old money and connected folk. They are trying to commercialize a very OLD drug that has not been taken forward because it needs to be synthesized as the natural version is too rare. Most, if not all of the research on this drug has been paid for by the U.S. government.
Two years ago I stated my discomfort with the way this company came into being and was run: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=128690545
Shortly after this was posted the Pump and Dump I prophesied was realized and a great deal of retail money was taken out of the U.S. market, minimizing the risk of the founding stockholders.
Retail will continue to get the short end of the stick here to the bitter end. I will not invest in this company because I know how it ends... If the science is not successful the company goes broke and retail will be the bagholder. If it is successful read to the end of this post to find the outcome.
I will continue to add to this research as time permits.
This drug is owned by old money "non profit" institutions. These are the two most prominent in the story:
Rockefeller Neuroscience Institute https://directory.hsc.wvu.edu/Department/2192
Woods Hole Oceanographic Institution
The initial investors have been selling stock to recoup their initial cost of funding the company on price spikes and replenishing it with warrants.
I am not convinced that treating Alzheimer's is the primary goal of Neurotrope. It is also not clear that people who buy stock in NTRP will be the primary beneficiaries if the company is successful. I suspect it will be the founding stockholders who have probably already made most of their "investment" back by selling at higher prices.
I am also not sure if there is solid protection for the IP as with proof of concept someone might design a new synthetic chemical that could do it all better. They have patents but I don't know how enforceable they would be against a newly designed chemical.
I think Anavex may draw the ire of NTRP proponents because 2-73 achieves the same goal of neurogenesis with a chemical that clearly does not fall under their IP umbrella. I also believe we will be on the market sooner with a drug that is much more economical than theirs making their franchise worthless....
... and then there's 3-71.
This is how it plays out historically:
OLD NEWS - on Bryostatin and Cancer:
Source: DGNews | Posted 17 years ago
FDA Grants Orphan Drug Designation To Bryostatin-1, In Combination With Taxol (Paclitaxel), For Esophageal Cancer
Read/Add Comments | Email This | Print This
MARTINSRIED/MUNICH, GERMANY and WALTHAM/BOSTON, MA -- December 12, 2001 -- GPC Biotech AG, a leading genomics- and proteomics-driven drug discovery and development company, announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for its Phase II clinical compound Bryostatin-1 in combination with Taxol (paclitaxel) for the treatment of esophageal cancer.
The orphan drug designation allows GPC Biotech exclusive marketing rights for the esophageal cancer indication in the US on Bryostatin-1 for seven years following marketing approval by the FDA. The designation also enables GPC Biotech to apply for research funding, tax credits on certain research expenses and a waiver from the FDA's application user fee.
Preliminary results from a current Phase II study at Memorial Sloan Kettering Cancer Center suggest that Bryostatin-1 increases tumor response when used in combination with Taxol against esophageal cancer.
GPC Biotech plans to advance Bryostatin-1 through Phase III clinical studies in combination with Taxol for the treatment of esophageal cancer as well as other clinical trials in additional indications if the clinical results continue to be positive.
In addition to the clinical trials for esophageal cancer, Bryostatin-1 is currently in a number of additional Phase II human clinical trials in combination with other therapeutics for several different indications.
Bryostatin-1 is linked to the modulation of Protein Kinase C (PKC), a well-validated anti-cancer target. PKC is an attractive target for cancer chemotherapy as this kinase family plays a fundamental role in the development of cancer through regulating cell growth and programmed cell death (apoptosis).
Esophageal cancer is a devastating disease with a tremendous unmet medical need. The FDA's orphan drug designation is intended to encourage research and development of new therapies for diseases that affect fewer than 200,000 US residents.
SOURCE: GPC Biotech AG
Bryostatin 1 Induces Biphasic Activation of Protein Kinase D in Intact Cells*
Sharon A. Matthews‡, George R. Pettit§ and Enrique Rozengurt‡¶
+ Author Affiliations
From the ‡Growth Regulation Laboratory, Imperial Cancer Research Fund, 44 Lincoln’s Inn Fields, London WC2A?3PX, United Kingdom, and the §Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe,?Arizona?85287
Bryostatin 1 and phorbol esters are both potent activators of protein kinase C (PKC), although their specific biological effects can differ in many systems. Here, we report that bryostatin 1 activates protein kinase D (PKD), a novel serine/threonine protein kinase, in intact Swiss 3T3 cells and secondary mouse embryo fibroblasts and in COS-7 cells transiently transfected with a PKD expression construct. The dose response of PKD activation induced by bryostatin 1 follows a striking biphasic pattern with maximal activation achieved at a concentration of 10 nM. Higher concentrations of bryostatin 1 (100 nM) reduced PKD activation induced by phorbol 12,13-dibutyrate to levels stimulated by bryostatin 1 alone. Bryostatin 1-induced PKD activation was markedly attenuated by treatment of cells with the PKC inhibitors bisindolylmaleimide I and Ro 31-8220. However, these agents did not inhibit PKD activity when added directly to in vitro kinase assays, suggesting that bryostatin 1 stimulates PKD activation through a PKC-dependent pathway in intact cells. Our results raise the possibility that activated PKD in intact cells could mediate some of the multiple biphasic biological responses induced by bryostatin 1.
Bryostatin 1 is a natural macrocyclic lactone with potent antineoplastic properties in a variety of animal models (1-3) and has entered clinical trials as a potential therapeutic agent (4, 5). Bryostatin family members bind to and activate classic and novel isoforms of protein kinase C (PKC)1 (6-9), the major cellular targets of the tumor-promoting phorbol esters (10). Despite appearing to bind to the same cellular targets, the biological responses induced by bryostatin 1 frequently differ from those induced by phorbol esters. For example, many bryostatin 1-mediated effects have unusual characteristics such as biphasic dose-response relationships, delayed kinetics, and the ability to inhibit phorbol ester-induced responses (7, 11-16). The precise mechanism(s) by which bryostatin 1 induces these biological effects remain poorly understood.
The newly identified protein kinase D (PKD) is a mouse serine/threonine protein kinase with distinct structural features and enzymological properties (17-19). In particular, the catalytic domain of PKD, which is distantly related to Ca2+-regulated kinases, shows little homology to the highly conserved regions of the kinase domain of the PKC family. As a consequence of this, PKD does not phosphorylate a variety of known PKC substrates, indicating that PKD has a distinct substrate specificity (18, 19).
The amino-terminal region of PKD contains a putative transmembrane domain, two cysteine-rich zinc finger-like motifs, and a pleckstrin homology domain. Unlike all known PKC isoforms, PKD does not contain a pseudosubstrate motif upstream of the cysteine-rich region, and the sequence separating the cysteine-rich repeats of PKD (95 amino acids) is substantially longer than that of classical and novel PKCs (28 and 35 amino acids, respectively). Additionally, residues Ala-146, Ala-154, and Tyr-182 in the consensus cysteine-rich motif of PKD differ from those found in PKCs. However, both immunopurified PKD and a fusion protein containing the cysteine-rich region of PKD bind phorbol esters with high affinity, and PKD is directly stimulated in vitroby these agents, or by diacylglycerol, in the presence of phospholipids (18, 19). A human protein kinase called atypical PKCµ (20) with 92% homology to PKD is also stimulated in vitro by phorbol esters and phospholipids (21). These results indicate that PKD/PKCµ are phorbol ester/diacylglycerol-stimulated protein kinases. Recent studies have demonstrated a novel mechanism of activation of PKD. Specifically, treatment of intact cells with biologically active phorbol esters induces phosphorylation-dependent activation of PKD through a PKC-dependent pathway (22). PKD activity recovered from phorbol ester-stimulated cells can be measured by kinase assays in the absence of lipid activators. These results revealed an unsuspected connection between PKCs and PKD and suggested that PKD can function parallel to and/or downstream of PKC in signal transduction pathways.
The differences between the biological effects elicited by phorbol esters and bryostatin 1 in certain systems prompted us to examine whether bryostatin 1 regulates PKD activity in intact cells. Here we report that treatment with bryostatin 1 induces PKD activation in intact Swiss 3T3 cells and MEF and in COS-7 cells transfected with a PKD expression vector. A salient feature of our results is that bryostatin 1-mediated activation of PKD follows a striking biphasic dose-response relationship. PKD activation induced by treatment with PDB was inhibited by high concentrations of bryostatin 1. These results raise the possibility that PKD could mediate some of the multiple biological responses induced by bryostatin 1.
Quote: https://en.wikipedia.org/wiki/GPC_Biotech About Altana - and how retail got screwed...
GPC Biotech AG
GPC Biotech logo orange.png
Founded August 1997
Location Martinsried, Germany
Key people Bernd R. Seizinger, M.D., Ph. D. (CEO)
Mirko Scherer, Ph. D. (CFO)
Products 3 in Clinical or Pre-clinical development
Revenue €12,649 (2004)
GPC Biotech (also referred to as GPCbiotech and GPC-Biotech) was a German biopharmaceutical company. The company's mission statement reads "... to discover, develop and commercialize new anticancer drugs."
Founded in 1997, the company was held privately until May 2000 when an initial public offering was made on the now defunct German Neuer Markt. Subsequent to the closing of the Neuer, GPC refinanced in June 2004 through a public stock offering and listed ADRs on NASDAQ.
In March 2000, the company acquired Mitotix, a United States biotechnology firm located in Cambridge, Massachusetts. This acquisition has led to the company having ~50% of its employees based in the United States and the remaining 50% in Germany. Further, the acquisition of Mitotix provided convenient proximity to GPC's long term and continuing collaboration with ALTANA Pharma AG and the ALTANA Research Institute, located in Waltham, Massachusetts.
In November 2009, Agennix AG acquired GPC Biotech .
In 2013 Agennix AG went into liquidation.
Altana's roots go back to 1873, when Heinrich Byk founded the chemicals factory Dr. Heinrich Byk Chemische Fabrik in Oranienburg. The company grew, and in 1931 it was renamed BYK-Gulden Lomberg. In 1941 majority control of the company was acquired by AFA (Akkumulatoren-Fabrik AG) which was renamed VARTA in 1962. In 1977 VARTA was split into three companies, one of which was Altana.
From 1977 to 2010, Altana was publicly traded on the Frankfurt Stock Exchange. Altana was also admitted to trading on the New York Stock Exchange from 2002 to 2007.
On December 19, 2006 the majority of shareholders voted to approve the sale of the pharmaceuticals division to the Danish company Nycomed. Nycomed is owned by an investment consortium led by Nordic Capital and Credit Suisse. With the sale of the pharmaceuticals division, headquartered in Konstanz, Germany, Altana lost a major pillar of its business. At that time, 9,000 of the company’s 13,500 employees were working for Altana in the pharmaceuticals sector, generating two-thirds of the company’s total revenue. And indeed, the balance-sheet revenues fell by around 60 percent in 2006, but gained over six percent in 2007.
The patent for pantaprazole, the main revenue-generator for the former pharmaceuticals division, expired in 2009/2010. While the Altana Management Board justified the divestiture of the pharmaceutical business with delays in the approval of new products, increased research and development costs as well as strict regulatory requirements in the US and Europe, shareholder activists asserted that the Management Board had invested too little in the pharmaceutical business in the preceding years and had failed to develop successor products in time to compensate for the revenue losses to be expected due to the expiry of the pantaprazole patent at the end of the decade.
The pharmaceuticals division was sold for €4.6 billion. The entire proceeds from the sale were disbursed to the shareholders, who received a special dividend of €33 per share. Critics expressed discontent that the main shareholder benefited most from the sale of the pharmaceuticals division.
Until January 1, 2007, the company was organized into the pharmaceuticals division Altana Pharma AG, formerly Byk Gulden Lomberg Chemische Fabrik, headquartered in Konstanz, and the specialty chemicals division Altana Chemie AG based in Wesel. Since the sale of the pharmaceutical business to Nycomed, Altana has been operating exclusively in the specialty chemicals segment. This restructuring was accompanied by a change in the company logo, which was unified across all subsidiaries.
On November 6, 2008, main shareholder SKion GmbH (Germany, owned by Susanne Klatten) issued a public takeover offer of €13 per share for all outstanding shares, an action which drove up the stock price. A company spokesperson stated that the intention was to delist the company from public trading. To achieve this, SKion issued a second takeover offer of €14 per share to the remaining shareholders on November 9, 2009.
On December 30, 2008, the Frankfurt Stock Exchange announced that Altana would be removed from its MDAX index, as the increase in the share held by SKion had pushed the portion of stock held in free float to under ten percent. By June 2010, SKion held 95.04 percent of all shares.
In Germany, the stock was traded mainly on the Frankfurt and Stuttgart Exchanges and the Xetra platform; internationally, it was admitted to trading on the London Stock Exchange and the NASD Group, now FINRA, in the US.
After SKion acquired the entire Altana stock through a squeeze-out, trading in this stock was suspended effective August 27, 2010.
From Wikipedia, the free encyclopedia
Jump to navigationJump to search
2017-09-12 IAA 2017 Susanne Klatten bei BMW by Olaf Kosinsky-10.jpg
Born Susanne Hanna Ursula Quandt
28 April 1962 (age 56)
Bad Homburg, Germany
Residence Bad Homburg
Education IMD-Lausanne (MBA)
Known for holdings in Altana and BMW; richest woman in Germany
Net worth US$25.1 billion (March 2018)
Spouse(s) Jan Klatten (m. 1990)
Children 3 
Parent(s) Herbert Quandt (1910–1982)
Johanna Quandt (1926–2015)
Relatives Stefan Quandt (brother; b. 1966)
Susanne Klatten (born Susanne Hanna Ursula Quandt on 28 April 1962) is a German heiress, the daughter of Herbert and Johanna Quandt. As of March 2018, her net worth was US$25.1 billion, making her the richest woman in Germany and the 38th richest person in the world.